The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

There are currently two drugs that are approved by the Food and Drug Administration (FDA) to treat diffuse large B-cell ...

Roche will present the new data at next week's ASCO congress showing that its bispecific antibody glofitamab can achieve high and durable responses in patients with aggressive lymphoma.

Roche (OTCQX:RHHBY) said the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended ...

As a rough comparison, in a similar trial population glofitamab had an overall response rate of 52%, with 39% complete responses, with 78% of them responding for 12 months or more. “The FDA ...

About the STARGLO study The STARGLO study [GO41944; NCT04408638] is a phase III, multicentre, open-label, randomised study evaluating the efficacy and safety of Columvi® (glofitamab) in combination ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Columvi® (glofitamab) in ...